Arvinas (ARVN) Net Cash Flow (2017 - 2026)
Arvinas (ARVN) posted quarterly Net Cash Flow of -$55.6 million for Q1 2026, down 185.13% year-over-year from $65.3 million in Q1 2025, and down 234.3% quarter-over-quarter from $41.4 million in Q4 2025.
Analysis
Arvinas (ARVN) Net Cash Flow (2017 - 2026) Analysis & Trends
Arvinas' Net Cash Flow history runs 10 years deep, the most recent figure standing at -$55.6 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 185.13% year-over-year to -$55.6 million; the TTM figure through Mar 2026 stood at $6.3 million (up 150.4% YoY), while the FY2025 annual figure was $42.4 million, up 119.57% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$55.6 million, down from $41.4 million in the prior quarter.
- The five-year high for Net Cash Flow was $198.0 million in Q4 2023, with the low at -$223.7 million in Q1 2024.
- The 5-year median for Net Cash Flow is $15.3 million (2024), against an average of -$1.5 million.
- The sharpest annual moves came in 2023 and 2024: Net Cash Flow soared 485.96% in 2023, then sank 557.46% in 2024.
- Arvinas' Net Cash Flow stood at -$51.3 million in 2022, then jumped by 485.96% to $198.0 million in 2023, then tumbled by 92.27% to $15.3 million in 2024, then surged by 170.59% to $41.4 million in 2025, then plunged by 234.3% to -$55.6 million in 2026.
- Business Quant data shows ARVN's Net Cash Flow at -$55.6 million in Q1 2026, $41.4 million in Q4 2025, and -$13.4 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -183.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | 374.50 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 407.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | -496,000.00 |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 225.59 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Arvinas | 605.88 Mn | 37.98 Mn | - | 7.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.00 Mn |
| Mar 31, 2026 | -55.60 Mn |
| Dec 31, 2025 | 41.40 Mn |
| Sep 30, 2025 | -13.40 Mn |
| Jun 30, 2025 | 33.90 Mn |
| Mar 31, 2025 | -19.50 Mn |
| Dec 31, 2024 | 15.30 Mn |
| Sep 30, 2024 | -75.10 Mn |
| Jun 30, 2024 | 66.80 Mn |
| Mar 31, 2024 | -223.70 Mn |
| Dec 31, 2023 | 198.00 Mn |
| Sep 30, 2023 | 23.10 Mn |
| Jun 30, 2023 | -39.60 Mn |
| Mar 31, 2023 | 48.90 Mn |
| Dec 31, 2022 | -51.30 Mn |
| Sep 30, 2022 | 40.40 Mn |
| Jun 30, 2022 | 30.90 Mn |
| Mar 31, 2022 | -46.00 Mn |
| Dec 31, 2021 | -147.40 Mn |
| Sep 30, 2021 | 207.00 Mn |